Immune system activation for cancer treatment
ARMO BioSciences was a late-stage immuno-oncology biotech company developing a pipeline of novel proprietary product candidates, including pegilodecakin (AM0010), to activate the immune system for treating solid tumors and cancers. The company was acquired by Eli Lilly in 2020 for $1.6 billion.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2018
Aug 2017
Feb 2016
May 2014
Nov 2013
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
